|

apatinib plus camrelizumab Clinical Trials

2 actively recruiting trials

Also known as: Apa plus C

Top Sponsors

  • Ze-yang Ding, MD1
  • Tongji Hospital1

Indications

  • Liver Disease2
  • Hepatocellular Carcinoma Non-resectable2
  • Liver Cancer2
  • Cancer2

Other2 trials

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.